A global clinical trial has identified fluvoxamine, a widely available antidepressant, as a potential treatment for persistent fatigue in patients with long COVID. According to findings published in the Annals of Internal Medicine, the medication demonstrated a 99 percent probability of being more effective than a placebo in reducing exhaustion and improving quality of life for adults struggling with the condition for at least 90 days post-infection.
Clinical Evidence for Fluvoxamine
The REVIVE-TOGETHER trial, a collaborative effort involving researchers from McMaster University, Stanford University, and several Brazilian institutions, tested 399 adults in Brazil. Participants were randomly assigned to receive fluvoxamine, metformin, or a placebo for 60 days. The study, co-led by McMaster’s Edward Mills, found that fluvoxamine provided consistent benefits for those experiencing long-term fatigue.
“This is an important step forward for patients who have been desperate for evidence-based options,” said Mills, a professor in McMaster’s Department of Health Research Methods, Evidence, and Impact. Because the drug is already well-understood and inexpensive, researchers believe it has significant potential for clinical application.
Did you know?
The REVIVE-TOGETHER trial utilized a Bayesian adaptive design. This allowed researchers to stop individual treatment groups early once the evidence reached a sufficient threshold of clarity, making the study faster and more efficient than traditional clinical trials.
Comparing Treatment Outcomes: Fluvoxamine vs. Metformin
While fluvoxamine showed promise, the trial results for metformin were different. Despite previous research suggesting that metformin could reduce the risk of developing long COVID if taken during an initial SARS-CoV-2 infection, it did not provide meaningful relief for those who had already developed established long COVID fatigue.
The contrast between these two drugs highlights the complexity of treating the condition. According to Gilmar Reis, a lead author and researcher with the Brazilian clinical research center Cardresearch, the study’s adaptive design was essential to reaching these conclusions quickly. The trial was funded by The Latona Foundation.
Managing Long COVID Fatigue Today
With an estimated 65 million people affected by long COVID globally, the search for effective therapies remains a priority. Researchers emphasize that while fluvoxamine is a significant finding, it is not a “cure-all.” Long COVID involves a wide range of symptoms and biological processes, and the medication’s primary success in this trial was limited to fatigue management.
Currently, most medical guidance focuses on supportive care, such as activity pacing and symptom-specific management. Jamie Forrest, a postdoctoral research fellow at the University of British Columbia, notes that the trial provides the first strong evidence for a medication that can help, bringing patients closer to having a viable clinical option.
Pro Tip:
If you are living with long COVID symptoms, keep a symptom diary to track how your energy levels fluctuate. This data is often helpful for clinicians when discussing potential treatment pathways or lifestyle adjustments.
Frequently Asked Questions
Is fluvoxamine a cure for long COVID?
No. According to the study authors, fluvoxamine is not a complete solution. It specifically showed promise in reducing fatigue, but it does not address all symptoms or biological processes associated with long COVID.
Why did the study use a Bayesian adaptive design?
This design allowed researchers to reach reliable conclusions more quickly than traditional trials by stopping treatment groups early once the evidence became clear, without sacrificing scientific rigor.
Can I start taking fluvoxamine for long COVID immediately?
Patients should consult with their healthcare provider to discuss these findings. The study provides evidence for clinical use, but doctors must determine if the medication is appropriate for an individual’s specific health profile.
Did metformin work for long COVID fatigue?
In this specific trial, metformin did not produce meaningful improvement for participants who already had established long COVID fatigue, despite its reported benefits in preventing the condition when taken during an initial infection.
Have you or a loved one been impacted by long COVID symptoms? Share your experiences in the comments below, or subscribe to our newsletter for the latest updates on clinical research and health breakthroughs.
Related reading